{"url_path":"/sec/axsm/8-k/2026-06-09/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-09","source_url":"https://www.sec.gov/Archives/edgar/data/1579428/0001193125-26-264043-index.html","accession_number":"0001193125-26-264043","cik":"0001579428","ticker":"AXSM","issuer_name":"Axsome Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1579428/0001193125-26-264043-index.html","primary_entity_key":"0001579428","primary_entity_name":"Axsome Therapeutics, Inc."},"word_count":391,"has_tables":true,"body_markdown":"Item 5.07 Submission of Matters to a Vote of Security Holders.\n\nAt the 2026 Annual Meeting of Stockholders of Axsome Therapeutics, Inc. (the “Company”) held on June 5, 2026 (the “Annual Meeting”), the following proposals were submitted to the stockholders of the Company:\n\n \n\nProposal 1: The election of two directors to serve as Class II directors until the Company’s 2029 annual meeting of stockholders and until their successors are duly elected and qualified;\n\n \n\nProposal 2: The ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026; and\n\n \n\nProposal 3: The approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers;\n\n \n\nFor more information about the foregoing proposals, see the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 24, 2026 (the “Proxy Statement”). Of the 51,439,952 shares of the Company’s common stock entitled to vote at the Annual Meeting, 43,777,536 shares, or approximately 85.10%, were represented at the meeting in person or by proxy, constituting a quorum. The number of votes cast for, against or withheld, as well as abstentions and broker non-votes, if applicable, in respect of each such proposal is set forth below:\n\n \n\nProposal 1: Election of Class II Directors.\n\n \n\nThe Company’s stockholders elected the following directors to serve as Class II directors until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified. The votes regarding the election of the Class II directors were as follows:\n\n \n\nDirector\n\n \n\nVotes For\n\n \n\nVotes Withheld\n\n \n\nBroker Non-Votes\n\n \n\nMark Saad\n\n \n\n28,675,654\n\n \n\n10,286,822\n\n \n\n4,815,060\n\n \n\nSusan Mahony, Ph.D., MBA\n\n \n\n29,892,131\n\n \n\n9,070,345\n\n \n\n4,815,060\n\n \n\n \n\nProposal 2: Ratification of Appointment of Deloitte & Touche LLP.\n\n \n\nThe Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes regarding this proposal were as follows:\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nVotes For\n\n \n\nVotes Against\n\n \n\nVotes Abstaining\n\n \n\nBroker Non-Votes\n\n \n\n43,278,147\n\n \n\n14,407\n\n \n\n484,982\n\n \n\n0\n\n \n\n \n\nProposal 3: Approval, by Non-Binding Advisory Vote, of the Compensation of the Company’s Named Executive Officers.\n\n \n\nThe Company’s stockholders voted to approve, by non-binding advisory vote, the compensation of the Company’s named executive officers. The votes regarding this proposal were as follows:\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nVotes For\n\n \n\nVotes Against\n\n \n\nVotes Abstaining\n\n \n\nBroker Non-Votes\n\n \n\n37,818,384\n\n \n\n777,937\n\n \n\n366,155\n\n \n\n4,815,060"}